Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma

Phase 1

Recruiting

Conditions: Follicular Lymphoma

Interventions: Diagnostic Test: cfDNA testing
Other: sample of saliva or fingernail clipping
Diagnostic Test: pre-treatment test specimen
Diagnostic Test: PET/CT, CT, or MRI testing

First Posted Date: 2020-07-13

Last Posted Date: 2024-08-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 100

Registration Number: NCT04468841

Locations: 🇺🇸
Memorial Sloan Kettering Commack (All Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

and more 4 locations

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Phase 1

Active, not recruiting

Conditions: Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma
Indolent Non-Hodgkin Lymphoma
Marginal Zone Lymphoma
Primary CNS Lymphoma
Diffuse Large B Cell Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Chronic Lymphocytic Leukemia
Waldenstrom Macroglobulinemia
Burkitt's Lymphoma

Interventions: Drug: 19(T2)28z1xx CAR T cells

First Posted Date: 2020-07-09

Last Posted Date: 2024-08-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT04464200

Locations: 🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 4 locations

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Phase 1

Completed

Conditions: Thyroid Carcinoma
Thyroid Cancer
Thyroid Cancer, Follicular
Thyroid Cancer (Follicular Cell)
Thyroid Cancer, Papillary
BRAF V600E Mutation Positive

Interventions: Diagnostic Test: I-124 PET/CT lesion dosimetry
Drug: Vemurafenib
Drug: Copanlisib

First Posted Date: 2020-07-08

Last Posted Date: 2024-02-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT04462471

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center (All protocol activities), New York, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States

and more 4 locations

Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma
Non-Hodgkin Lymphoma
Hodgkin Disease

Interventions: Other: Acupuncture
Drug: opioid
Other: Assessments

First Posted Date: 2020-07-07

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 299

Registration Number: NCT04459416

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Seattle Cancel Care Alliance (Data Collection Only), Seattle, Washington, United States

Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer

Not Applicable

Recruiting

Conditions: Early Stage Breast Cancer

Interventions: Other: Aerobic Training

First Posted Date: 2020-07-07

Last Posted Date: 2024-10-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 152

Registration Number: NCT04458532

Locations: 🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital (Data Collection Only), Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of PRP Treatment for Hair Loss After Cancer Therapy in Women With Breast Cancer

Early Phase 1

Active, not recruiting

Conditions: Alopecia

Interventions: Procedure: Platelet Rich Plasma system

First Posted Date: 2020-07-07

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT04459650

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Adenocarcinoma

Interventions: Drug: Temozolomide (TMZ)
Drug: Cisplatin
Drug: Nivolumab

First Posted Date: 2020-07-07

Last Posted Date: 2024-03-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT04457284

Locations: 🇺🇸
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States

and more 4 locations

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

Not Applicable

Active, not recruiting

Conditions: High Grade Ovarian Serous
Ovarian Cancer

Interventions: Diagnostic Test: PET/MRI
Diagnostic Test: Contrast enhanced CT

First Posted Date: 2020-07-01

Last Posted Date: 2024-03-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT04454450

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

A New Psychotherapy Intervention for Older Cancer Patients

Not Applicable

Recruiting

Conditions: Cancer

Interventions: Behavioral: Social Work and Supportive Counseling (SWSC) Intervention

First Posted Date: 2020-06-30

Last Posted Date: 2024-10-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 335

Registration Number: NCT04452825

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Phase 2

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: Obinutuzumab
Drug: Venetoclax

First Posted Date: 2020-06-25

Last Posted Date: 2024-12-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 100

Registration Number: NCT04447768

Locations: 🇺🇸
Stanford University Medical Center (Data collection only), Stanford, California, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack (All protocol activities), Commack, New York, United States

and more 5 locations

Home Terms & Conditions Privacy Policy